



Panel Discussion: Establishment of a Biosimilar Economic Dashboard to Inform Organizational Strategy

Moderator: Dina Dumercy McHenry, PharmD, MBA, BCOP, CSSGB, CPh
Director of Pharmacy

Courtney Zephir, MBA
Manager of Pharmacy Business Affairs

Halena Leah Marcelin, PharmD, MS, CPh, 340B ACE
Director, Pharmacy Business Affairs

Alga Ramos, PharmD, MS, MBA, BCPS, BCOP, CSSGB
Oncology Pharmacy Manager

Objectives

- Discuss the development of a Biosimilar Dashboard and Steering Committee
- Review example dashboard and case study
- Evaluate operational considerations for implementation



Pharmacy Business Affairs Team

340B & Procurement Compliance

- Ensures system-wide 340B compliance
- Monitors and navigates pharmacy procurement-related activities and compliance

Pharmacy Finance


- Bridges the gap between pharmacy and finance teams
- Responsible for all pharmacy-related financial activities

Pharmacy Charge Management

- Supports Revenue Cycle Management teams
- Provides support for decision making utilizing data analytics



Biosimilar Dashboard and Steering Committee Development



Example Template



Recommendations: Reference

- 1: Biosimilar 1 (Manufacturer)
- 2: Biosimilar 2 (Manufacturer)
- 3: Biosimilar 3 (Manufacturer)

Biosimilar Contracts			
	# of Vials	Vial 1	Vial 2
Tier 1			
Tier 2			
Tier 3			

Financial Class	OP Payor Mix	IP Payor Mix
Medicare	40%	0.00%
Medicaid	5%	0.00%
Market Place	5%	0.00%
Commercial	40%	100.00%
Other*	10%	0.00%


*Other represents International, Charity, Self Pay, Workers Comp, Other, and Blank financial classes.



All values displays are for example purposes only



Monitoring Biosimilar Adoption



Operational Implementation

Clinical Considerations

- Indications
- Excipients (reactions, tolerability)
- Beyond use date/stability

Preferred products

- Establish tiers

Payer Mix Guidelines

- Understand crosswalk

The Best Choice	S	
2nd Best Choice	A	
Good But Not Great	B	
This is average	C	
Slightly Below Average	D	
Below Average	E	
The Worst Choice	F	



Operational Implementation

Informatics

Business Office Collaboration

- Tiered approach
- Powerform for visibility

Pharmacist Involvement

- Dispensing

Inventory Management

- PAR Levels
- Wholesaler Allocations

PreAuthorization Chemotherapy

ONC Approval/No Auth Required: See Comments

Medications Approved: (08/22)(AETNA) AETNA-

{ (08/22)(AETNA) AETNA-

*Medications Not Approved: **NO*

*Comments: **IF MEDICATION IS NOT LISTED ** DO NOT ADMINISTER ** SEE*





Panel Discussion: Establishment of a Biosimilar Economic Dashboard to Inform Organizational Strategy

Moderator: Dina Dumercy McHenry, PharmD, MBA, BCOP, CSSGB, CPh
Director of Pharmacy

Courtney Zephir, MBA
Manager of Pharmacy Business Affairs

Halena Leah Marcelin, PharmD, MS, CPh, 340B ACE
Director, Pharmacy Business Affairs

Alga Ramos, PharmD, MS, MBA, BCPS, BCOP, CSSGB
Oncology Pharmacy Manager